Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.
Back to dashboard
Company Information
About this company
Key people
Justin W. Yorke
Independent Chairman of the Board
Geraldine Liu Pannu
Independent Director
George K. Ng
Chief Executive Officer, Director
Wendy Guy
Founder, Chief Administrative Officer
Russell L. Skibsted
Chief Financial Officer
David Young
President - Research and Development, Director
Patrick Lin
Chief Business and Strategy Officer
Sheila Gujrathi
Director
Khoso Baluch
Independent Director
James R. Neal
Independent Director
Click to see more
Key facts
- Shares in issue2.79m
- EPICPCSA
- ISINUS74275C4033
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$4.72m
- Employees12
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.